The FDA accepts MRK's BLA for clesrovimab, its monoclonal antibody, to protect infants from RSV disease. A decision from the ...

Bank of America Securities analyst Graham Parry has maintained their bearish stance on GSK stock, giving a Sell rating on December 11.Pick the ...

The FDA has started a review of MSD's respiratory syncytial virus (RSV) antibody clesrovimab, with a verdict due in the ...

Request To Download Free Sample of This Strategic Report@ COPD and asthma devices are crucial in the management and treatment of respiratory diseases, providing relief and improving the quality of ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...

GlaxoSmithKline (GSK)’s B7-H3-targeted antibody-drug conjugate (ADC), GSK’227 has gained priority medicines (PRIME) ...

But enrollment for all clinical studies of infant RSV vaccines is now on hold due to safety concerns, explained a Dec. 11 ...

GSK is hosting the third annual RespiVerse Meeting in Bangkok, Thailand. The event brings together renowned international ...

The news followed an investigation by POLITICO's E&E News into climate-friendly inhalers and how drug giants are developing ...

The revenue for GSK-3810109 is expected to reach an annual total of $132 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...

Researchers identified optimal assessment tools for RSV, influenza, and hMPV that accurately supplement the identification of ...

Linerixibat is a small molecule commercialized by GSK, with a leading Phase III program in Pruritus. According to Globaldata, it is involved in 15 clinical trials, of which 12 were completed, and 3 ...